標(biāo)題: Titlebook: Applied Peritoneal Dialysis; Improving Patient Ou Anjay Rastogi,Edgar V. Lerma,Joanne M. Bargman Book 2021 Springer Nature Switzerland AG 2 [打印本頁(yè)] 作者: FROM 時(shí)間: 2025-3-21 19:41
書(shū)目名稱Applied Peritoneal Dialysis影響因子(影響力)
作者: 草率女 時(shí)間: 2025-3-21 22:08 作者: 入會(huì) 時(shí)間: 2025-3-22 01:06 作者: TEN 時(shí)間: 2025-3-22 08:35 作者: 起來(lái)了 時(shí)間: 2025-3-22 10:47 作者: 蒼白 時(shí)間: 2025-3-22 15:09 作者: Panther 時(shí)間: 2025-3-22 20:03 作者: AXIOM 時(shí)間: 2025-3-22 23:52 作者: Liberate 時(shí)間: 2025-3-23 04:23 作者: 以煙熏消毒 時(shí)間: 2025-3-23 07:28
https://doi.org/10.1007/978-3-642-97972-9nted to explain the evolution of thought on the topic, with emphasis on the current appreciation of residual kidney function as an important contributor to peritoneal dialysis adequacy. It concludes with some practical recommendations related to preservation of residual kidney function as well as wa作者: 業(yè)余愛(ài)好者 時(shí)間: 2025-3-23 10:33
https://doi.org/10.1007/978-3-642-97972-9ns over the last four decades. Technology and techniques to perform peritoneal dialysis (PD) have evolved and, in its current form, are reliable, easy to use, and come at an acceptable cost. Also, various regimens and modes of PD allow for social interaction and optimizing PD efficiency in terms of 作者: incontinence 時(shí)間: 2025-3-23 16:50 作者: 可憎 時(shí)間: 2025-3-23 18:43
https://doi.org/10.1007/978-3-662-21880-8 goals of solute clearance as well as fluid removal (ultrafiltration). The initial PD prescription should take into account several factors such as the patient’s desired lifestyle, residual renal clearance, fluid status, and desired type of PD. The initial prescription should be evaluated, along wit作者: 啪心兒跳動(dòng) 時(shí)間: 2025-3-23 22:48 作者: Frenetic 時(shí)間: 2025-3-24 05:41
Weitere Entzifferungen unbekannter Schriftento a lesser extent catheter exit-site infections are leading causes of PD morbidity, and peritonitis is a major cause of transfer to HD. Certain procedures, both at the time of catheter placement and subsequently during maintenance PD therapy, can reduce the risk of PD-related infections. Empiric an作者: 古代 時(shí)間: 2025-3-24 07:27 作者: JUST 時(shí)間: 2025-3-24 12:06
Entzinkung von Gichtstaub im Schmelzzyklonrmone (PTH), calcitriol (1,25-dihydroxyvitamin D), which is the active metabolite of vitamin D, and fibroblast growth factor 23 (FGF-23). Circulating or soluble klotho also plays a role in mineral homeostasis. These hormones act on four primary target organs: the bone, kidney, intestine, and parathy作者: 盤(pán)旋 時(shí)間: 2025-3-24 16:38
Entzinkung von Gichtstaub im Schmelzzyklonuremia and persistence of associated middle molecule molecular toxins. With the advent of the kidney X initiative, growth of peritoneal dialysis (PD) is expected to greatly increase the number of patients on home therapies. In this chapter, the pathophysiology of anemia in ESKD is discussed in detai作者: 退潮 時(shí)間: 2025-3-24 20:41
Graft-versus-host-disease (GVHD) tringent a control is not advisable. Blood pressure control is necessary. Although there are many theoretical concerns on the choice of individual anti-hypertensive agent, the decision is usually obvious in real-life practice because most patients require multiple agents. For hypercholesterolemia, c作者: Palliation 時(shí)間: 2025-3-25 02:10 作者: 制定 時(shí)間: 2025-3-25 04:07
978-3-030-70899-3Springer Nature Switzerland AG 2021作者: 無(wú)脊椎 時(shí)間: 2025-3-25 09:05
Anjay Rastogi,Edgar V. Lerma,Joanne M. BargmanUp-to-date resource for all clinical aspects of peritoneal dialysis.Practical and easy to read in-depth review.Authored by leaders in the field.Fills a critical gap in the literature作者: Malcontent 時(shí)間: 2025-3-25 12:35
http://image.papertrans.cn/b/image/160029.jpg作者: mastoid-bone 時(shí)間: 2025-3-25 18:21 作者: 蛙鳴聲 時(shí)間: 2025-3-25 20:32 作者: inundate 時(shí)間: 2025-3-26 03:07
Muster im polyalphabetischen Fall, bowel perforation is observed in less than 1% of procedures..A successful percutaneous PD catheter insertion program can have a positive impact on PD utilization in high- and low-resource settings alike. It is incumbent upon all interventional nephrologists to review their catheter outcomes in a t作者: employor 時(shí)間: 2025-3-26 08:13
https://doi.org/10.1007/978-3-642-97972-9D (manual or automated). These strategies allow for using tidal PD (TPD), continuous flow peritoneal dialysis (CFPD), assisted peritoneal dialysis, urgent-start PD, incremental PD, and remote patient monitoring (RPM) in clinical practice [.]. We will also outline various approaches that can further 作者: BRAWL 時(shí)間: 2025-3-26 10:04 作者: 填滿 時(shí)間: 2025-3-26 14:39
https://doi.org/10.1007/978-3-662-21880-8eter-related outcomes similar to patients who start PD in a conventional manner. Moreover, clinical outcomes, hospitalizations, and infections in urgent-start PD patients appear to be similar if not better than patients who start HD with a CVC. In this chapter, we will present the definition of urge作者: 蜿蜒而流 時(shí)間: 2025-3-26 19:27 作者: Etching 時(shí)間: 2025-3-26 23:45
Entzinkung von Gichtstaub im Schmelzzyklon and phosphorus by altering the production of calcitriol, PTH, FGF-23, and klotho. Eventually these compensatory responses become unable to maintain normal mineral homeostasis, resulting in (1) altered serum concentrations of calcium, phosphorus, PTH, calcitriol, FGF-23, and klotho, (2) disturbances作者: Debate 時(shí)間: 2025-3-27 02:46
Graft-versus-host-disease (GVHD) new-onset diabetes. For those with pre-existing diabetes, worsening of diabetic control seems uncommon, unless the patient needs hypertonic cycles. Non-glucose-based PD solution may make diabetic control easier in some patients.作者: Alopecia-Areata 時(shí)間: 2025-3-27 05:52 作者: NUL 時(shí)間: 2025-3-27 12:41
Physiology of Peritoneal Dialysis,l equilibration test is used in clinical practice to evaluate the peritoneal solute transfer rate of individual patients and patients are divided into high, high average, low average, or low transporter groups. Morphological changes occur in the peritoneal membrane in patients over time in long-term作者: 大笑 時(shí)間: 2025-3-27 16:47 作者: neutralize 時(shí)間: 2025-3-27 20:23
,Peritoneal Dialysis Catheter Insertion by?the Nephrologist,, bowel perforation is observed in less than 1% of procedures..A successful percutaneous PD catheter insertion program can have a positive impact on PD utilization in high- and low-resource settings alike. It is incumbent upon all interventional nephrologists to review their catheter outcomes in a t作者: mercenary 時(shí)間: 2025-3-28 01:03
Techniques in Peritoneal Dialysis,D (manual or automated). These strategies allow for using tidal PD (TPD), continuous flow peritoneal dialysis (CFPD), assisted peritoneal dialysis, urgent-start PD, incremental PD, and remote patient monitoring (RPM) in clinical practice [.]. We will also outline various approaches that can further 作者: neoplasm 時(shí)間: 2025-3-28 03:07 作者: 柱廊 時(shí)間: 2025-3-28 07:02
Urgent-Start Peritoneal Dialysis,eter-related outcomes similar to patients who start PD in a conventional manner. Moreover, clinical outcomes, hospitalizations, and infections in urgent-start PD patients appear to be similar if not better than patients who start HD with a CVC. In this chapter, we will present the definition of urge作者: achlorhydria 時(shí)間: 2025-3-28 12:11 作者: 新奇 時(shí)間: 2025-3-28 17:31
ESKD Complications: CKD-MBD, and phosphorus by altering the production of calcitriol, PTH, FGF-23, and klotho. Eventually these compensatory responses become unable to maintain normal mineral homeostasis, resulting in (1) altered serum concentrations of calcium, phosphorus, PTH, calcitriol, FGF-23, and klotho, (2) disturbances作者: calumniate 時(shí)間: 2025-3-28 21:30
Peritoneal Dialysis in Diabetic Patients, new-onset diabetes. For those with pre-existing diabetes, worsening of diabetic control seems uncommon, unless the patient needs hypertonic cycles. Non-glucose-based PD solution may make diabetic control easier in some patients.作者: 貝雷帽 時(shí)間: 2025-3-29 01:30 作者: ABOUT 時(shí)間: 2025-3-29 04:50 作者: 防水 時(shí)間: 2025-3-29 08:15 作者: OASIS 時(shí)間: 2025-3-29 14:31
Entzinkung von Gichtstaub im Schmelzzyklonxia-inducible factor-prolyl hydroxylase inhibitors). Finally factors unique to PD are discussed to crystalize the unique challenges and opportunities inherent in treating ESKD-associated anemia in PD patients.作者: 采納 時(shí)間: 2025-3-29 18:03
History of Peritoneal Dialysis,p an appreciation for the amount of research, innovation, and perseverance that lead to the current status of PD. This chapter will outline the history of PD and review a number of major scientific breakthroughs that have collectively shaped how PD is currently practiced.作者: 民間傳說(shuō) 時(shí)間: 2025-3-29 20:38
The Evolution of Peritoneal Dialysis Solutions,lysate. The durability of PD as a dialysis modality depends on the type of solution utilized and its long-term effects on the peritoneal membrane. Many have argued that biocompatible solutions are ideal because they are proposed to limit the long-term degradation of the peritoneal membrane.作者: MOT 時(shí)間: 2025-3-30 01:05 作者: 團(tuán)結(jié) 時(shí)間: 2025-3-30 07:54
Anemia Management in Peritoneal Dialysis,xia-inducible factor-prolyl hydroxylase inhibitors). Finally factors unique to PD are discussed to crystalize the unique challenges and opportunities inherent in treating ESKD-associated anemia in PD patients.作者: tympanometry 時(shí)間: 2025-3-30 11:36 作者: BADGE 時(shí)間: 2025-3-30 15:34 作者: 不能約 時(shí)間: 2025-3-30 19:02 作者: 裂口 時(shí)間: 2025-3-30 20:48 作者: cipher 時(shí)間: 2025-3-31 02:42
Peritoneal Dialysis Access: Catheters and Placement,ods of catheter placement include percutaneous needle-guidewire, open dissection, peritoneoscopy, and laparoscopy. The selected approach must consider patient factors, facility resources, and the expertise and availability of the operating team.作者: 脫落 時(shí)間: 2025-3-31 07:37 作者: 內(nèi)部 時(shí)間: 2025-3-31 09:52
,Continuous Ambulatory Peritoneal Dialysis Versus Automated Peritoneal Dialysis – Are There Differen, or health-related quality of life in individuals undergoing CAPD compared with those undergoing APD. Given these considerations, it appears that patient choice should drive the decision about PD modality.
